ANALYSIS OF PHARMACOTHERAPEUTIC APPROACH IN PATIENTS WITH HYPERTHYROIDISM
Abstract
Introduction: Hyperthyroidism represents a condition that occurs due to increased synthesis of thyroid hormones (T3, T4). In 90% of all cases it is caused by: Graves disease, toxic multinodular goiter and toxic adenoma. Therapy of hyperthyroidism includes medication, radioiodine treatment and surgery. The most prescribed antithyroid drugs belong to the thioamide group (thiamazole and propylthiouracil).Aim: The aim of this study was to analyze the preoperative pharmacotherapeutic approach with the use of 3 drugs from the thioamide group (PTU® (propylthiouracil), Thyrozol® (thiamazole) and Tiastat® (thiamazole)) in patients with hyperthyroidism.Material and methods: The study was conducted as a retrospective study among 62 patients aged 18 to 84 years, who reported to the Center for Endocrine Surgery KCS for the operative treatment of hyperthyroidism in period of 2014-2019.Results: Diagnosis of Graves disease was detected in 35.48% of patients, 32.26% had toxic multinodular goiter, and 32.26% toxic adenoma. The most patients (45.16%) were prescribed Tiastat®, 29.03% of them were prescribed PTU®, and 25.8% of them Thyrozol®. The most of patients suffered from Graves disease were treated with Tiastat®, those suffered from toxic adenoma with PTU® and with toxic multinodular goiter with Tiastat®. The most commonly used doses were 100 mg/day for PTU®, 20 mg/day for Tiastat® and 20 and 30 mg/day for Thyrozol®. Total thyroidectomy is most commonly performed in patients treated with Tiastat® and hemithyroidectomy in those treated with PTU®.Conclusion: The most of patients were prescribed Tiastat®. It was observed that there was a statistically significant difference (p˂0.05) in the use of individual drugs regarding to diagnosis, total daily dose of drug, BMI and type of surgical procedure.Key words: hyperthyroidism, pharmacotherapy, thiamazole, propylthiouracil, thyroidectomy
References
2. Vanderpump MPJ. The epidemiology of thyroid disease. Br Med Bull. 2011. Sep;99(1):39–51.
3. Varagić V, Milošević M. Tireoidni hormoni i antitireoidni lekovi. In: Varagić V, Milošević M. editors. Farmakologija. dvadesettreće izdanje. Beograd. ELIT MEDICA; 2012. p. 475-477.
4. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977 Dec;7(6):481–93.
5. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995 Jul;43(1):55–68.
6. Ministarstvo zdravlja Republike Srbije, Republička stručna komisija za izradu vodiča dobre kliničke prakse, Nacionalni vodič dobre kliničke prakse za poremećaj rada štitaste žlezde, [Online][pristup februar 2020] Available from: https://www.zdravlje.gov.rs/tekst/335903/nacionalni-vodici-dobre-klinicke-prakse.php
7. Panzer C, Beazley R, Braverman L. Rapid preoperative preparation for severe hyperthyroid Graves’ disease. J Clin Endocrinol Metab. 2004 May;89(5):2142–4.
8. Goichot B, Caron P, Landron F, Bouee S. Clinical presentation of hyperthyroidism in a large representative sample of outpatients in France: relationships with age, aetiology and hormonal parameters. Clin Endocrinol (Oxf). 2016 Mar;84(3):445–51.
9. Abraham-Nordling M, Bystrom K, Torring O, Lantz M, Berg G, Calissendorff J, et al. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol. 2011 Dec;165(6):899–905.
10. Asvold BO, Bjoro T, Nilsen TIL, Vatten LJ. Tobacco smoking and thyroid function: a population-based study. Arch Intern Med. 2007 Jul;167(13):1428–32.
11. Rios-Prego M, Anibarro L, Sanshes-Sobrinno P. Relationship between thyroid dysfunction and body weight: a not so evident paradigm. Int J Gen Med. 2019 Aug;12: 299–304.
12. Boelaert K. Thyroid dysfunction in the elderly. Nat Rev Endocrinol. 2013 Apr;9(4):194–204.
13. Diez JJ. Hyperthyroidism in patients older than 55 years: an analysis of the etiology and management. Gerontology. 2003;49(5):316–23.
14. Agencija za lekove i medicinska sredstva Srbije. Sažetak karakteristika leka THYROZOL. [Online][pristup februar 2020] Available from: http://www.alims.gov.rs/download/smpc/3924-2008-12.pdf.
15. Agencija za lekove i medicinska sredstva Srbije. Sažetak karakteristika leka TIASTAT. [Online][pristup februar 2020] Available from: http://www.alims.gov.rs/download/smpc/1228-2008-12.pdf.
16. Agencija za lekove i medicinska sredstva Srbije. Sažetak karakteristika leka PTU. [Online][pristup februar 2020] Available from: http://www.alims.gov.rs/download/smpc/2631-2009-12.pdf.
17. DeGroot LJ, Mangklabruks A, McCormick M. Comparison of RA 131I treatment protocols for Graves’ disease. J Endocrinol Invest. 1990 Feb;13(2):111–8.
18. Bron LP, O’Brien CJ. Total thyroidectomy for clinically benign disease of the thyroid gland. Br J Surg. 2004 May;91(5):569–74.
19. Nair GC, C Babu MJ, Menon R, Jacob P. Preoperative Preparation of Hyperthyroidism for Thyroidectomy - Role of Supersaturated Iodine and Lithium Carbonate. 2018;22(3):392-396.
20. Fischli S, Lucchini B, Muller W, Slahor L, Henzen C. Rapid preoperative blockage of thyroid hormone production / secretion in patients with Graves’ disease. Swiss Med Wkly. 2016;146:w14243.
21. Ross D, Burch H, Cooper D, Greenlee C, Laurberg P, Maia AL et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. 2016;26(10):1355-69.